ORIC
- ORIC Pharmaceuticals, Inc.
()
Overview
Company Summary
ORIC Pharmaceuticals, Inc. (ORIC) is a biopharmaceutical company that focuses on the development of novel therapies for the treatment of cancer. The main goal of ORIC is to address the significant unmet medical needs in oncology by targeting the mechanisms of resistance to existing cancer therapies.
One of the key areas of expertise for ORIC is the development of small molecule inhibitors that target specific proteins involved in cancer cell resistance. The company aims to develop therapies that can overcome or prevent the resistance mechanisms that often emerge following treatment with traditional cancer drugs.
ORIC has a particular focus on two main areas of resistance. The first is the development of therapies that target the glucocorticoid receptor (GR) pathway, which is responsible for a variety of resistance mechanisms in several types of cancer. By inhibiting GR, ORIC aims to enhance the effectiveness of existing cancer therapeutics.
The second area of focus for ORIC is the development of therapies that target the heat shock protein 90 (HSP90) pathway, which is involved in the development of resistance to cancer treatments. By targeting HSP90, ORIC aims to disrupt the signal pathways that promote resistance and enhance the efficacy of existing cancer drugs.
Overall, ORIC Pharmaceuticals, Inc. is dedicated to advancing the field of oncology by developing innovative therapies that can overcome resistance mechanisms in cancer cells. By targeting specific proteins and pathways, ORIC aims to improve the treatment outcomes for cancer patients and provide new options for those facing limited therapeutic options.